±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 415  |  »Ø¸´: 3
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

rhett82

½ð³æ (СÓÐÃûÆø)

ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...

[½»Á÷] ҩѧ´Ê»ã

ҩѧÃû´Ê£¨ÖÐ-Ó¢£©

6-Á×ËáÆÏÌÑÌÇÍÑÇâø glucose-6-phosphate dehydrogenase
Janbon×ÛºÏÖ¢ Janbon's syndrome
PPBŨ¶È parts per billion concentration
pphmŨ¶È parts per hundred million concentration
PPHŨ¶È parts per hundred concentration
ppmŨ¶È parts per million concentration
°²È«·¶Î§ safety range
°²È«ÊÔÑé·¨ innocuity test method
°²È«ÏµÍ³ safety coefficient
°²Î¿¼Á placebo
òüºÏ¼Á chelating agent
°Ðϸ°û target cell
°×µ°°×΢ÇòÖÆ¼Á albumin microballoons
°Ù·ÖŨ¶È percentage concentration
°ëºÏ³É¿¹ÉúËØ semisynthetic antibiotics
°ë¿¹Ô­ haptene
°ëÊýÖÂËÀ¼ÁÁ¿ half lethal dose ; median lethal dose; LD50
°ëË¥ÆÚ half-life period; half life time
°üÒÂÆ¬ coated tablet
±¡Ä¤Ò film-coating
±¥ºÍÈÜÒº saturated solution
±´¿ËÀÕ¶û Becquerel
±»¶¯ÃâÒß passive immunity
±»¶¯×ªÔË passive transport
±À½â¶È disintegration
±À½â¼Á disintegrants
±ØÐè°±»ùËá essential aminoacid
±ØÐèÖ¬·¾Ëá essential fatty acid
±ä̬·´Ó¦ allergy; allergic reaction
±íÃæ»îÐÔ surface activity
±íÃæÕÅÁ¦ surface tension
±ûÖÖÉäÏß gamma rays
²¹Ìå complement
²¹Ìåϵͳ complement system
²»Á¼·´Ó¦ adverse reaction
²»ÍêÈ«¿¹Ô­ incomplete antigen
²ë¼Á liniments
³¤ÆÚ¶¾ÐÔʵÑé long term toxicity test
³¤Ð§ÖƼÁ prolonged action preparation
³¦¸ÎÑ­»· enterohepatic circulation
³¦ÈÜ¿ØÊÍÆ¬ enteric controlled release tablets
³¦ÈÜÒ enteric coating
´¦·½ prescription;recipe
´©Í¸´Ù½ø¼Á penetration enhancers
´ÅÐÔ¿ØÊÍÖÆ¼Á magnetic controlled release dosage form
´ÅÐÔÒ©ÎïÖÆ¼Á magnetic medicinal preparations
´ó·Ö×Ó macromolecule
µ¥¿Ë¡¿¹Ìå monoclonal antibody
µ¨¼îõ¥Ã¸ cholinesterase
µ±Á¿ equivalent weight
µ±Á¿¶¨ÂÉ equivalent law
µ±Á¿Å¨¶È normality
µ±Á¿ÈÜÒº normal solution
µÈÕÅÈÜÒº isotonic solution
µÍ¾ÛÌÇ oligosaccharides
µÍÃܶÈÖ¬µ°°× low density lipoprotein
µÎ¶¨ titration
µÎ¶¨ÇúÏß titration curve
µÎÍè¼Á pill
µÝÖÊ transmitter
µç½â electrolyzation
µç½âÖÊ electrolyte
ôú¼Á tincture
¶¨ÏòÒ©ÎïÖÆ¼Á directed pharmaceutical preparations
¶¾Àíѧ toxicology
¶¾ÐÔ·´Ó¦ toxic response; toxic reaction
¶ÌÆÚÖ°©ÊµÑé short term carcinogenic test
¶ÔÒòÖÎÁÆ etiological treatment
¶ÔÓ³Ìå antipode
¶ÔÖ¢ÖÎÁÆ symptomatic treatment
¶à¹¦ÄÜø multifunctional enzyme
¶à¼ÁÁ¿¸øÒ© multiple dose administration
¶àÌÇ polyose
¶àëÄ polypeptide
¶ù²è·Ó°· catecholamine
¶þÖØ¸ÐȾ superinfection
·¢½Í fermentation
·¨¶¨´¦·½ official formula
·¼×廯ºÏÎï aromatic compound
·ÅÉä¶¾Àíѧ radiotoxicology
·ÅÉäÒ©¼Áѧ radiopharmaceutics
·Ç±ØÐè°±»ùËá non-essential amino acid
·ÇÈ¥¼«»¯Ðͼ¡ËÉÒ© nondepolarizer
·Ö×Ó²¡ molecular disease
·Ö×ÓÈÜÒº molecular solution
·Ö×ÓÉúÎïѧ molecular biology
·Ö×ÓÒ©Àíѧ molecular pharmacology
¸¨»ù prosthetic group
¸¨ÁÏ excipients
¸¨Ã¸ coenzyme
¸±×÷Óà side effect
¸½¼Ó¼Á additive
¸ÉÔï¼Á desiccant;drying agent
¸ÎÊ×¹ýЧӦ first pass effect of hepar
¸ÐÊÜÆ÷ receptor
¸ßÃôÐÔ hyperreactivity
¸öÌå²îÒìÐÔ individual differences; individual variation
¸øÒ©·½°¸»ò¸øÒ©ËÙ¶È dosage regimen or dose rate
¸øÒ©¼ä¸ô dosing interval
¹¤ÒµÒ©¼Áѧ industrial pharmacy
¹²¼Û¼ü covalent bond
¹âÁ¿×Ó light quantum
¹ãÆ×¿¹ÉúËØ broad-spectrum antibiotic
¹ýÂË filtration
¹ýÃô¶¾ËØ anaphylatoxin
¹ýÃôÐÔÒ©Îï·´Ó¦ anaphylactic drug reaction
¹ýÑõ»¯Îï superoxide
º¬Á¿¾ùÔÈ¶È content uniformity
ºËÌǺËËá ribonucleic acid; RNA
ºËÜÕËá nucleotide
ºÏ²¢ÓÃÒ© drug combination
ºÏ³ÉÒ©Îï synthetic drugs
ºÏ¼Á mixture
ºÛÁ¿ÔªËØ trace element
»¯Ñ§·ÖÎö chemical analysis
»¯Ñ§ÎïÀíѧ chemical physics
»¯Ñ§Ïû¶¾·¨ chemical disinfection
»¯Ñ§Ò©ÎïÖÎÁÆ chemotherapy
»·¾³Ò©Àíѧ environmental pharmacology
»ù±¾Ò©Îï essential drugs
»ùÒò gene
¼¤»î¼Á activator
¼¤»î×÷Óà activation
¼¤ËØ hormone
¼¤ËØÔ­ prohormone
¼±ÐÔ¶¾ÐÔʵÑé acute toxicity test
¼ºÌÇ´¼Ï¸°û¶¾¼Á cytotoxic hexitols
¼ÁÁ¿ dosage; dose
¼ÁÁ¿»òŨ¶ÈµÄÒÀ´æÐÔ dose or concentration dependency
¼ÁÐÍ dosage form
¼ä½ÓÖ°© indirect carcinogenesis
¼äЪÃð¾ú·¨ discontinuous sterilization
¼îÖж¾ alkalosis;alkali-poisoning
½ºÌåÈÜÒºÐÍÒ©¼Á medical colloidal solution
½ÀÓÃÆ¬ chewable tablets
½Í½â glycolysis
Þ׿¹×÷Óà antagonism
½â¶¾×÷Óà detoxication
½éÖÊ mediator; transmitter; medium
¾«ÉñÒÀÀµÐÔ psychic dependence
¾çÒ© powerful drug
¾ø¶ÔÖÂËÀ¼ÁÁ¿ absolute lethal dose; LD100
¿¹¶¾ËØ antitoxin
¿¹¾úÆ× antibacterial spectrum
¿¹Ìå antibody
¿¹ÑªÇå antiserum
¿¹Ò©ÐÔ resistance to drugs
¿¹Ô­ antigen
¿Ëµ±Á¿ gram-equivalent weight
¿Ëµ±Á¿Êý gram-equivalent number
¿Ë·Ö×Ó gram-molecule; gram-mol
¿Ë·Ö×Ó·ÖÊý molar fraction
¿Ë·Ö×ÓÁ¿ gram molecular weight
¿Ë·Ö×ÓŨ¶È molar comcentratin; molal comcentration
¿ËÔ­×Ó gram-atom
¿ØÊÍÖÆ¼Á controlled release preparation
¿ÚÇ»ÄÚ¸øÒ© oral administration
¿ìËÙÄÍÊÜ tachyphylaxis
À©É¢ diffusion
À©É¢ÏµÊý coefficient of diffusion
ÀÛ»ýÄòÅÅйÇúÏß cumulative urinary excretion curves
ÀÛ¼ÓЧӦ additive effect
Àà¶¾ËØ anatoxin;toxoid
Àà¹Ì´¼Í£Ò©×ÛºÏÕ÷ steroid withdrawal syndrome
À䲨 cold-storage
Àä¶³ freezing;refrigeration
Á¿×ÓÒ©Àíѧ quantum pharmacology
ÁÙ´²Ò©Àíѧ clinical pharmacology
ÁÙ´²Ò©Ñ§ chlinical pharmacy
±»¯Îï halogenide
ÂñÖ²¼Á implants
ÂýͨµÀ slow pathway
ÂýÐÔ¶¾ÐÔʵÑé chronic toxicity test; long term toxicity test
ø enzyme
øԭ proenzyme
ÃâÒßÒÖÖÆ¼Á immunosuppressant;immuno inhibitor
ÃâÒßÔ­ÐÔ immunogenicity
ÃâÒßÔöÇ¿¼Á immunoenhancement
Ãô¸ÐÐÔ sensitivity
Ħ¶û mole
Ħ¶û·ÖÊýŨ¶È mol fraction concentration
Ħ¶û·Ö×ÓÌå»ý molar volume;mole volume
Ħ¶ûŨ¶È molarity
Ĭ¿ËË÷Òý the Merck index
ÄÍÊÜÐÔ tolerance
ÄÍÒ©ÐÔ drug tolerance
ÄÚ¶¾ËØ endotoxin
ÄÚ¶¾ËØö×ÊÔ¼Á²â¶¨·¨ Limulus Amebocyte Lysate assay for endotoxin
ÄÚÏûÐýÌå mesomer
Ũ¶È concentration
Ƥ·ô¡¢Õ³Ä¤±íÃæ¸øÒ© skin and mucocutaneous administration
Ƭ¼ÁÓ²¶È tablet hardness
ÆøÄý½º aerogel
ÆøÈܽº aerosol
ÆøÌå·ÖÎö gas analysis
ÆøÎí¼Á aerosol
ǰÌåÒ©Îï prodrug
ÇÊÄÚ×¢Éä intrathecal injection
ȫøÓ븨»ù holonzyme and prosthetic group
È˹¤ºÏ³É¿¹Ô­ artificial antigen
È˹¤ÃâÒß artificial immunization
ÈËÖÖÒ©Àíѧ ethnopharmacology
ÈÕÄÚÍßÃüÃû·¨ Geneva nomenclature
ÈܼÁ solvent; dissolvent
Èܽâ dissolution; dissolving
Èܾúø lysozyme
ÈÜѪ hemolysis
ÈÜÖÊ solute
ÈýôÈËáÑ­»· tricarboxylic acid cycle
ɱ¾ú»îÐÔ bactericidal activity
ɱ¾ú×÷Óà bactericidal effect
ÉíÌåÒÀÀµÐÔ physical dependence
Éñ¾­¶¾ËØ neurotoxin
ÉöÉÏÏÙËØÄÜÉñ¾­ adrenergic nerve
ÉöÉÏÏÙËØÄÜÊÜÌå adrenergic receptor
ÉøÍ¸Ñ¹ osmotic pressure
Éú³¤ÇúÏß growth curve
ÉúÎï°· biogenic amine
ÉúÎï°ëË¥ÆÚ biological half life
ÉúÎﻯѧ biochemistry
ÉúÎï¼î alkaloid
ÉúÎïÀûÓÃ¶È bioavailability
ÉúÎïͳ¼ÆÑ§ biometrics;biometry
ÉúÎïÒ©¼Áѧ biopharmacy
ÉúÎïÖÆÆ· biological product
ÉúÒ© crude drugs
ʱ³½Ò©Àíѧ chronopharmacology
ʱ¼ä¸ÐÊÜÐÔ chronosusceptability
ʱ¼äÖÎÁÆ chronotherapy
ʱЧ¹ØÏµ time-effect relationship
ʱֵ chronaxia;chronaxy
ʱÖÍ lag time
ÊÀ½çÎÀÉú×éÖ¯ World Health Organization; WHO
ÊɾúÌå bacteriophage
ÊÕÁ²Ò© astringent
ÊÖÐÔÒ©Îï chiral drug
Ê×¹ýЧӦ first-pass effect
ÊÜÌå receptor
ÊÜÌ弤¶¯¼Á receptor stimulant
ÊÜÌåÞ׿¹¼Á receptor antagonist
˫ä·¨ double-blind technique
Ë®½â£¨×÷Óã© hydrolysis
ÌÇÒìÉú×÷Óà gluconeogenesis
Ìå±íÃæ»ý body surface area
Ìå»ý±ÈŨ¶È volume by volume concentration
ÌåÒº body fluid
ÌåÒºÃâÒß humoral immunity
ÌìÈ»¿¹Ìå natural antibody
ÌìÈ»¿¹Ô­ natural antigen
ÌìÈ»ÃâÒß natural immunity
ÌìȻҩÎï crude drugs; natural drugs
µ÷¼Áѧ dispensing pharmacy
Í¬Î»ËØ isotope
Í»±ä mutation
ÍÌÊÉ×÷Óà phagocytosis
Íâ¶¾ËØ exotoxin
ÍâÏûÐýÌå raceme
ÍêÈ«¿¹Ô­ complete antigen
ÍõË® aqua regia; nitrohydrochloric acid
΢Á£Ìåø microsomal enzyme
΢Á¿ÔªËØ trace element
ÎÈ̬ѪҩŨ¶È steady state plasma concentration
ÎïÀíÒ©¼Áѧ physical pharmaceutics
ÎüÈë·¨ inhalation
ÎüÊÕËÙÂʳ£Êý absorption rate constant
ϸ°ûÃâÒß cellular immunity
ÏÙÜÕÁ×Ëá adenosine phosphate
ÏÞÖÆÐÔ¾çÒ© restrictive holagogue
Ïà¶Ô¸øÒ©¼ä¸ô relative dosage interval
Ïà¼Ó×÷Óà additive effect; addition
Ïò°Ð¸øÒ© targetable drug delivery
Ïû³ýËÙÂʳ£Êý elimination rate constant
Ч¼Û potency
Ч¼Ûµ¥Î» potency unit
Ч¼ÛÇ¿¶È potency
ЧӦ effect
ЧӦÆ÷ effector
ЧӦÎï effector
Э¶¨´¦·½ cipher prescription
Эͬ×÷Óà synergism
ÐË·ÜÐÔ excitability
Ðò¹áÉè¼Æ sequential design
Ðü¸¡Òº suspension
Ñ¡ÔñÐÔ selectivity
Ѫ¹ÜÄÚ¸øÒ© intravascular administration
Ѫ¹ÜÍâ¸øÒ© extravascular administration
Ѫ½¬ plasma
Ѫ½¬´úÓÃÒº plasma substitute
Ѫ½¬µ°°×½áºÏÂÊ plasma protein binding ratio
ѪÄÔÆÁÕÏ blood-cerebral barrier
ѪÇå serum
ѪÈÝÁ¿À©³ä¼Á blood volume expander
ѪҩŨ¶È blood concentration
ѪҺÄý¹Ì blood coagulation
ÑªÒºÖÆÆ· blood products
ÑǼ±ÐÔÖж¾ subacute intoxication;subacute poisoning
ÑÇÏõËáÑÎÖж¾ nitrite poisoning
ÑÛÓÃĤ¼Á ocular inserts
Ò©¡ªÊ±°ë¶ÔÊýÇúÏß semi-logarithmic curve of drug-time
Ò©¡ªÊ±ÇúÏß drug-time curve
Ò©·åŨ¶È peak concentration of drug
Ò©·åʱ¼ä peak time of drug
Ò©¼ÁµÈЧÐÔ pharmaceutical equivalence
Ò©¼Áѧ pharmaceutics
Ò©Àíѧ pharmacology
Ò©ÃôÊÔÑé drug sensitive test
Ò©Æ·¸ºÔðÆÚ allotted date of drug quality ensuring by manufacturer
Ò©Æ·¹ÜÀí·¨ drug administration law
Ò©Æ·ÅúºÅ drug batch number
ҩƷʹÓÃÆÚ limit date of using a drug after its production
Ò©Æ·ÓÐЧÆÚ expiry date; date of expiration
Ò©Æ·ÖÊÁ¿±ê×¼ drug standard
Ò©Îï´úл drug metabolism
Ò©Îï´úлø drug metablic enzyme
Ò©ÎïµÄÌåÄÚ¹ý³Ì intracorporal process of drugs
Ò©ÎﶯÁ¦Ñ§Ä£ÐÍ pharmacokinetics model
Ò©Îï·´Ó¦ drug reaction
Ò©Îï·Ö²¼ drug distribution
Ò©Îï·ÖÎö pharmaceutical analysis
Ò©Îﻯѧ pharmaceutical chemistry
Ò©ÎïÅÅй drug excretion
Ò©ÎïÎüÊÕ drug absorption
Ò©ÎïÏ໥×÷Óà drug interaction
Ò©ÎïÏû³ý drug elimination
Ò©ÎïÐî»ý drug accumulation
Ò©Îïѧ pharmacology; materia medica
Ò©ÎïÒÅ´«Ñ§ pharmacogenetics
ҩЧ¶¯Á¦Ñ§ pharmacodynamics
Ò©Ô´ÐÔ¼²²¡ drug-induced diseases
ÒÒõ£µ¨¼îÒÒõ£µ¨¼î acetylcholine
ÒÒõ£µ¨¼îõ¥Ã¸ acetylcholinesterase
ÒÖ¾ú»îÐÔ bacteriostatic activity
ÒÖ¾ú×÷ÓÃ bactriostasis
Ò칹ø isomerase
ÓªÑøËØ nutrient
Ó²¸à¼Á plaster
ÓÐЧ°ëË¥ÆÚ effective halt
ÓÐЧÂÊ effective rate
ÓÐЧŨ¶È effective concentration
ÓÒÐýÌÇ dextrose
ÓÒÐýÌå dextrorotatory form
ãмÁÁ¿ threshold dose
ÔØÌå carrier
Ôíß° saponins
Ö¬ÖÊÌå liposome
Ö±³¦¸øÒ© rectal administration
Ö±ÏßÏà¹Ø linear correlation
Ö½ÐÍÆ¬¼Á oral medicaed soluble paper
Ö°©ÊµÑé carcinogenic test
Ö°©Îï carcinogen
Ö»ûÊÔÑé teratogenic test
Ö»ûÎï teratogen
ÖÂÃôÊÔÑé sensitization test
ÖÂÃô×÷ÓÃ sensitization
ÖÂËÀÁ¿ fatal dose; lethal dose
ÖÆ¼Á preparation
ÖÆ¼Áѧ technology of pharmaceutics
ÖÆÒ©»¯Ñ§ pharmaceutical chemistry
ÖÎÁƵÈЧ£¨Öµ£© therapeutic equivalence
ÖÎÁÆÁ¿ therapeutic dose
ÖÎÁÆÒ©ÎïÁÙ²â therapeutic drug monitoring; TDM
ÖÎÁÆÖ¸Êý therapeutic index TI
ÖÎÁÆ×÷Óà therapeutic action
Öж¾ intoxication; poisoning
ÖлªÈËÃñ¹²ºÍ¹úÎÀÉú²¿Ò©Æ·±ê×¼ Drug Standard of Ministry of Public Health of the People's Republic of China
ÖмäÌå intermediate
ÖúÂ˼Á filter aid
ÖúÈܼÁ complex solubilizer
ÖúÐü¼Á suspending agent
×ÔÉíÃâÒß autoimmunity
×é°· histamine
×î´óÄÍÊܼÁÁ¿ maximal tolerable dose; LDO
×î´óÎÞ×÷ÓüÁÁ¿ maxial noneffective dose; EDO
×îСÏÔÖø²îÊý least significant difference
×îСÓÐЧÁ¿ minimal effective dose
×îСÖÂËÀ¼ÁÁ¿ minimal lethal dose;MLD
×óÐýÌÇ levulose
×óÐýÌå levorotatory form
×ô¼Á adjuvant
»Ø¸´´ËÂ¥
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ÎÞÒ»Îï,ºÎ´¦Èdz¾°££®
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

wxmwqr

½ð³æ (СÓÐÃûÆø)

0.5

лл£¬Ï£Íû¼ÌÐøÀ©³ä¡£
4Â¥2006-05-22 20:55:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 4 ¸ö»Ø´ð

rhett82

½ð³æ (СÓÐÃûÆø)

ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...

´ó¼ÒÖ§³Öһϰɣ¡
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ÎÞÒ»Îï,ºÎ´¦Èdz¾°££®
2Â¥2006-05-16 17:33:18
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Çóµ÷¼Á +4 ͼ¼ø212 2026-03-30 4/200 2026-03-31 10:20 by cal0306
[¿¼ÑÐ] ±¾2Ò»Ö¾Ô¸C9-333·Ö£¬²ÄÁÏ¿ÆÑ§Ó빤³Ì£¬Çóµ÷¼Á +5 ÉýÉý²»½µ 2026-03-31 5/250 2026-03-31 09:18 by 535743368
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷½»288»¯¹¤×¨Ë¶Çóµ÷¼Á +4 ºÃÔ˺ÃÔË½Ó½Ó 2026-03-24 4/200 2026-03-31 09:18 by Î÷¾©Ñ§ÔºÍÁľ¹¤³
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ³õÊÔ346 +4 085601³õÊÔ346 2026-03-30 4/200 2026-03-31 07:47 by jp9609
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó×Ü·Ö298·Ö£¬Ç°Èý¿Æ223·Ö +10 dongfang59 2026-03-27 10/500 2026-03-30 23:42 by ¹û¹ûÂèßä
[¿¼ÑÐ] 085602»¯¹¤Çóµ÷¼Á£¨331·Ö£© +8 111@127 2026-03-30 8/400 2026-03-30 21:23 by Ñо¿É®µ¼µ¼
[¿¼ÑÐ] ²ÄÁÏ¿ÆÑ§Ó빤³Ì 317Çóµ÷¼Á +7 JKSOIID 2026-03-26 7/350 2026-03-30 20:10 by µÎµÎÉϰ¶Ñ½
[¿¼ÑÐ] Ò»Ö¾Ô¸£ºÎ÷±±´óѧ£¬Ó¢Ò»ÊýÒ»408-284·ÖÇóµ÷¼Á +5 12.27 2026-03-27 5/250 2026-03-30 19:31 by Ô´_2020
[¿¼ÑÐ] 318Çóµ÷¼Á +7 ³Â³¿79 2026-03-30 7/350 2026-03-30 10:49 by ̽123
[¿¼ÑÐ] 085600£¬²ÄÁÏÓ뻯¹¤321·ÖÇóµ÷¼Á +10 ´ó²öС×Ó 2026-03-28 10/500 2026-03-29 23:35 by ·ÉÐÐÈÕ¼ÇÎ÷
[¿¼ÑÐ] µ÷¼Á310 +12 ÎÂÈáµÄÍí°² 2026-03-25 13/650 2026-03-29 20:01 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 340Çóµ÷¼Á +6 Amber00 2026-03-26 6/300 2026-03-29 12:06 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 352·Ö-085602-Ò»Ö¾Ô¸985 +5 º£Äɰٴ¨Ly 2026-03-29 5/250 2026-03-29 09:57 by Sjndkwm
[¿¼ÑÐ] 0703»¯Ñ§Çóµ÷¼Á£¬¸÷λÀÏʦ¿´¿´ÎÒ£¡£¡£¡ +5 Æîì÷ì÷ 2026-03-25 5/250 2026-03-27 21:44 by ¶«·½ÖíÖí
[¿¼ÑÐ] ¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸ÄÏÅ©083200ʳƷ¿ÆÑ§Ó빤³Ì +5 XQTJZ 2026-03-26 5/250 2026-03-27 14:49 by ¿ñìÅÂóµ±µ±
[¿¼ÑÐ] 305Çóµ÷¼Á +5 ÍÛ¬¿¨¿â 2026-03-26 5/250 2026-03-27 14:01 by laoshidan
[¿¼ÑÐ] 0703»¯Ñ§338Çóµ÷¼Á£¡ +6 Zuhui0306 2026-03-26 7/350 2026-03-27 10:35 by shangxh
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©Óʵç´óѧ 288·Ö ²ÄÁÏ¿¼ÑÐ Çóµ÷¼Á +3 jl0720 2026-03-26 3/150 2026-03-26 13:39 by zzll406
[¿¼ÑÐ] ²ÄÁÏר˶ 335 ·ÖÇóµ÷¼Á +4 ¾Ü¾øÀ䱩Á¦ 2026-03-25 4/200 2026-03-25 18:45 by haxia
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏÓ뻯¹¤303·ÖÇóµ÷¼Á +4 Ϊѧ666 2026-03-24 4/200 2026-03-25 11:27 by BruceLiu320
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û